Nkarta, Inc. (NKTX) research
Nkarta, Inc.- Sector
- Biotechnology
- Last price
- $2.58
- As of
Nkarta, Inc. (NKTX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-10.
As of . Source: SEC EDGAR filings for NKTX. Method and limitations.
Share the NKTX intelligence card
See the full NKTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NKTX on one page. Preview it with sample data, then open it live with a free account.
Preview the NKTX dossierActive signals for NKTX
- highCONSENSUS_BUY
3 tracked funds increased NKTX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +77% to NKTX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +122% to NKTX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +4249% to NKTX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +62% to NKTX (2026Q2)
FREE, NO ACCOUNT
Every signal on NKTX, as it fires
You are seeing 5 of 12 signals recorded on NKTX since 2026-05-26.
The five above landed across 2 days. The other 7 were recorded on 3 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NKTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 65487U108 · 2026Q2 | $6.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 65487U108 · 2026Q2 | $5.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 65487U108 · 2026Q2 | $3.3M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 65487U108 · 2026Q2 | $916K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 65487U108 · 2026Q2 | $460K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 65487U108 · 2026Q2 | $302K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NKTX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
NKTX against its peers
NKTX's return on equity of -33.3% ranks in the 73rd percentile of 23 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | NKTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 19.0M USD | 7 | 14 |
| Operating margin | n/a | -354.5% | n/a | 14 |
| Net margin | n/a | -171.5% | n/a | 14 |
| Return on equity | -33.3% | -49.8% | 73 | 23 |
Peers (24): ORMP, ACOG, MSLE, PEPG, CNTN, CHRS, IPHA, PYXS, ADAG, NGEN, ORGO, MDWD, DTIL, CMPX, CUE, NAUT, AVXL, ALXO, ALEC, ELDN, XGN, TRDA, WHWK, ANTX. Left out: VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NKTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NKTX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NKTXand get the insider, 13F, options, and confluence read in one view.